|
|
|
| Safety analysis of Ticagrelor as an adjuvant medication for patients with acute coronary syndrome after percutaneous coronary intervention |
| ZHAO Zuan-hua1 TAN Jia-jin2▲ TAN Shun-pei1 |
1.Department of Pharmacy,Taishan People′s Hospital,Guangdong Province,Taishan 529200,China;
2.Department of Orthopedics,Taishan People′s Hospital,Guangdong Province,Taishan 529200,China |
|
|
|
|
Abstract Objective To analyze the safety of Ticagrelor as an adjuvant therapy for patients with acute coronary syndrome(ACS)after percutaneous coronary intervention(PCI).Methods From March 2018 to May 2020,60 ACS patients in Taishan People′s Hospital were selected as research subjects.According to the random number table method,they were divided into the control group and the study group,with 30 cases in each group.PCI was implemented according to China PCI Treatment Guideline 2012(concise).Patients after admission in the two groups were given load dose/conventional dose of Aspirin after PCI.In the control group,the load dose/conventional dose of Clopidogrel in oral administration after PCI was used;in the study group,oral administration of Ticagrelor at a load dose/conventional dose was added after PCI.The adverse cerebrovascular events,bleeding events,and adverse reactions were compared between the two groups within six months after surgery.Results There was no significant difference in the incidence of adverse cerebrovascular events after surgery in the two groups(P＞0.05).The incidence of postoperative bleeding events after surgery was lower than that of the control group,the difference was statistically significant(P＜0.05).The incidence of postoperative adverse reactions in the study group was lower than that of the control group,the difference was statistically significant(P＜0.05).Conclusion Ticagrelor has more advantages than Clopidogrel in reducing the incidence of adverse events and adverse reactions in patients with ACS,which is worthy of clinical promotion and application.
|
|
|
|
|
|
| [1] |
杨五小，来春林，陈福恒，等.应用Sonoclot 技术分析PCI术前使用阿司匹林、氯吡格雷、替格瑞洛对ACS 病人血小板功能的影响[J].中西医结合心脑血管病杂志，2017，4（15）：73-77.
|
| [2] |
殷蕾，李芳，陈立章.替格瑞洛与氯吡格雷用于中国急性冠状动脉综合征患者经皮冠状动脉介入术后疗效与安全性比较的Meta 分析[J].中国循环杂志，2017，32（10）：975-980.
|
| [3] |
姜荣泸，李正义.急性冠状动脉综合征患者PCI 术后长期应用替格瑞洛抗血小板治疗的疗效及安全性观察[J].解放军医药杂志，2017，29（12）：36-38，45.
|
| [4] |
张桂霞，李大鹏，王环宇，等.NSTE-ACS 患者PCI 术后应用替格瑞洛双抗血小板治疗的2年追踪分析[J].医学临床研究，2018，10（4）：672-674.
|
| [5] |
张新超，于学忠，陈凤英，等.急性冠脉综合征急诊快速诊治指南（2019）[J].中国急救医学，2019，39（4）：301-308.
|
| [6] |
中华医学会心血管病学分会介入心脏病学组，中华心血管病杂志编辑委员会.中国经皮冠状动脉介入治疗指南2012（简本）[J].中华心血管病杂志，2012，4（4）：50-59.
|
| [7] |
石凡.替格瑞洛与氯吡格雷用于急性冠脉综合征PCI 术疗效、安全性的前瞻性对照研究[J].心血管康复医学杂志，2018，27（5）：585-588.
|
| [8] |
李超，李毅，李晶，等.替格瑞洛和氯吡格雷治疗ACS 择期PCI 术后患者效果分析[J].心脏杂志，2017，29（6）：667-671.
|
| [9] |
陈曦，张海洋，孔繁亮，等.替格瑞洛联合西洛他唑在ACS患者PCI 术后抗血小板治疗中的应用[J].山东医药，2015，55（18）：43-45.
|
| [10] |
贺学魁，赵英娟.替格瑞洛改善NSTE-ACS 患者PCI 术后氯吡格雷抵抗的研究[J].中国循证心血管医学杂志，2017，9（2）：222-224，227.
|
| [11] |
孙雪梅，张春来，吕烨辉，等.替格瑞洛联合替罗非班在急性冠脉综合征患者PCI 术中的应用价值[J].中国现代医学杂志，2018，28（19）：117-122.
|
| [12] |
王彬.氯吡格雷、阿司匹林联合溶栓治疗急性ST 段抬高型心肌梗死的临床研究[J].现代预防医学，2012，39（11）：178-179．
|
| [13] |
刘佳，张晶.PCI 术后双联抗血小板治疗1年急性冠状动脉综合征患者应用不同抗血小板方案治疗的疗效和安全性比较[J].药物不良反应杂志，2017，19（5）：359-363.
|
| [14] |
郑艳娥，罗珲，杨航，等.替格瑞洛与氯吡格雷对ACS 患者PCI 术后抗血小板效果的比较[J].医学临床研究，2018，26（7）：1292-1295.
|
| [15] |
杨晓伟，张君毅，易甫，等.替格瑞洛对急性冠状动脉综合征择期介入治疗患者近中期疗效观察[J].中华临床医师杂志（电子版），2013，7（19）：8697-9700．
|
| [16] |
魏洪杰，石俊婷，张敏莉，等.替格瑞洛用于急性冠脉综合征患者经皮冠状动脉介入治疗的疗效及安全性[J].西部医学，2017，29（7）：978-981.
|
| [17] |
许祥，景涛，刘建平.替格瑞洛对急性冠脉综合征PCI 术后临床疗效观察[J].局解手术学杂志，2017，26（11）：834-837.
|
| [18] |
谭文鹏，李文杰，何晓青.替格瑞洛对急性冠脉综合征患者EMPs 和sICAM-1 的影响及预后观察[J].中国医药导报，2020，17（30）：142-145.
|
|
|
|
